tiprankstipranks
Trending News
More News >
Genscript Biotech (HK:1548)
:1548

Genscript Biotech (1548) AI Stock Analysis

Compare
6 Followers

Top Page

HK

Genscript Biotech

(OTC:1548)

Rating:64Neutral
Price Target:
HK$15.50
▲(6.02%Upside)
Genscript Biotech's strong technical performance and revenue growth are overshadowed by profitability challenges and valuation concerns. The stock's current bullish momentum may face resistance due to overbought conditions, and the negative P/E ratio raises questions about long-term viability. Improvements in profitability and cash management are crucial for enhancing the stock's appeal.

Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)

Genscript Biotech Business Overview & Revenue Model

Company DescriptionGenScript Biotech Corporation is a leading biotechnology company with a focus on life sciences research and application. The company provides a broad range of services and products including gene synthesis, peptide synthesis, protein engineering, and antibody production. Operating primarily in the life sciences sector, GenScript aims to accelerate the development of biopharmaceutical products and support advancements in healthcare and scientific research globally.
How the Company Makes MoneyGenScript Biotech primarily makes money through its diverse portfolio of products and services in the life sciences sector. The company's key revenue streams include custom gene synthesis, peptide and protein production, and antibody services, which are utilized by pharmaceutical companies, academic institutions, and research organizations worldwide. Additionally, GenScript has a strong presence in the cell therapy sector, offering products and services that support the development and commercialization of cell-based therapies. Strategic partnerships and collaborations with leading biotechnology and pharmaceutical companies further enhance its revenue potential, while its investment in research and development drives innovation and expands its market offerings.

Genscript Biotech Financial Statement Overview

Summary
Genscript Biotech shows significant revenue growth and a strong balance sheet, but struggles with profitability and consistent cash flow due to high capital expenditures and investments. The company needs to improve operational efficiency and manage capital expenditures better to ensure long-term financial health.
Income Statement
65
Positive
Genscript Biotech has shown significant revenue growth over the years, with a compound annual growth rate in revenue from 2019 to 2024. The gross profit margin remains strong, indicating efficient cost management. However, the company has struggled with profitability, as reflected in negative EBIT and net profit margins in several years, despite a positive net income in 2024 due to exceptional items. The trajectory indicates improving top-line growth but persistent challenges in achieving sustainable profitability.
Balance Sheet
75
Positive
The balance sheet reflects a strong equity position with the equity ratio consistently above 50%, indicating financial stability and low leverage. The debt-to-equity ratio is manageable, supporting a stable financial structure. Improvements in asset base and shareholder equity over the years suggest healthy growth, although fluctuations in cash reserves may indicate liquidity management challenges.
Cash Flow
60
Neutral
Cash flow from operations has improved in 2024, turning positive after several years of negative figures, demonstrating progress in cash generation. Nonetheless, the free cash flow remains negative, impacted by significant capital expenditures and investments, which could pose liquidity risks. The operating cash flow to net income ratio improved, but long-term sustainability of positive cash flow remains uncertain without consistent profitability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
594.49M839.53M625.70M490.10M390.85M
Gross Profit
272.13M409.55M304.08M282.52M255.89M
EBIT
9.28M-415.79M-438.11M-379.29M-204.55M
EBITDA
70.43M-249.42M-389.04M-341.57M-174.71M
Net Income Common Stockholders
2.96B-95.48M-226.85M-358.71M-204.94M
Balance SheetCash, Cash Equivalents and Short-Term Investments
621.18M1.93B1.46B1.41B772.38M
Total Assets
5.28B3.39B2.55B2.23B1.45B
Total Debt
723.74M416.99M349.80M156.45M55.00M
Net Debt
591.75M-1.03B-674.20M-1.02B-574.05M
Total Liabilities
954.91M1.34B1.18B846.17M631.82M
Stockholders Equity
4.32B1.39B1.01B1.05B901.71M
Cash FlowFree Cash Flow
-72.27M-444.62M-336.40M-269.83M-272.97M
Operating Cash Flow
75.65M-286.91M-120.29M-136.79M-151.09M
Investing Cash Flow
-1.46B-357.73M-443.30M-212.55M-100.17M
Financing Cash Flow
66.52M1.07B419.32M902.14M624.20M

Genscript Biotech Technical Analysis

Technical Analysis Sentiment
Positive
Last Price14.62
Price Trends
50DMA
11.48
Positive
100DMA
11.50
Positive
200DMA
11.51
Positive
Market Momentum
MACD
0.70
Negative
RSI
75.99
Negative
STOCH
81.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Positive. The current price of 14.62 is above the 20-day moving average (MA) of 11.89, above the 50-day MA of 11.48, and above the 200-day MA of 11.51, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 75.99 is Negative, neither overbought nor oversold. The STOCH value of 81.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1548.

Genscript Biotech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
HK$24.78B27.8631.65%4.23%47.71%
69
Neutral
HK$33.66B23.595.72%2.77%-15.81%-48.17%
64
Neutral
$31.66B0.97-6.09%41.41%7.26%
54
Neutral
HK$32.35B-19.78%25.96%39.58%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
53
Neutral
€32.65B-32.29%43.13%28.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1548
Genscript Biotech
14.62
5.52
60.66%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
71.40
20.30
39.73%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
45.60
26.76
142.04%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
21.35
9.17
75.29%
HK:9688
Zai Lab Ltd
29.65
13.75
86.48%

Genscript Biotech Corporate Events

GenScript Biotech’s Associate Unveils Promising Long-term Cancer Treatment Data
Jun 4, 2025

Legend Biotech, an associate of GenScript Biotech, announced promising five-year survival data from the CARTITUDE-1 study for its CARVYKTI® therapy in treating multiple myeloma. The data, presented at the 2025 ASCO Annual Meeting, showed that one-third of patients remained progression-free for five years, highlighting the therapy’s potential impact on long-term cancer treatment. Additionally, preliminary results from ongoing studies in solid tumors were also presented, indicating potential advancements in lung and gastric cancer therapies.

Genscript Biotech Announces AGM Results and Board Changes
May 29, 2025

Genscript Biotech Corporation held its Annual General Meeting on May 29, 2025, where all proposed resolutions were passed by poll. Key decisions included the re-election of several directors and the reappointment of Ernst & Young as auditors. The meeting also granted the board mandates to issue and repurchase shares, reflecting strategic moves to enhance corporate governance and shareholder value.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Genscript Biotech Announces Board Composition and Committee Roles
May 29, 2025

Genscript Biotech Corporation announced the composition and roles of its board of directors, highlighting the establishment of five committees to enhance governance and strategic oversight. This organizational update is likely to strengthen the company’s operational framework and could have implications for its strategic direction and stakeholder engagement.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Genscript Biotech Updates Nomination Committee Terms to Enhance Governance
May 29, 2025

Genscript Biotech Corporation has updated the terms of reference for its Nomination Committee, emphasizing the importance of diversity and independent oversight. The committee, which consists of at least three directors with a focus on gender diversity and independent non-executive directors, is tasked with reviewing the board’s structure and skills annually to align with the company’s corporate strategy. This move aims to enhance corporate governance and ensure the board’s composition supports strategic goals, potentially impacting stakeholder confidence positively.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Legend Biotech to Present New CARVYKTI Data at 2025 ASCO and EHA Meetings
May 22, 2025

Legend Biotech, an associate of Genscript Biotech, will present new data on CARVYKTI, a treatment for multiple myeloma, at the 2025 ASCO and EHA annual meetings. This announcement highlights the ongoing development efforts in the CARTITUDE Clinical Development Program, which could have significant implications for the treatment of multiple myeloma and potentially enhance Legend Biotech’s position in the biotech industry.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

GenScript Announces Legend Biotech’s Q1 2025 Financial Results
May 13, 2025

GenScript Biotech Corporation, a company incorporated in the Cayman Islands, has announced the financial results of its associate, Legend Biotech Corporation, for the first quarter ended March 31, 2025. Legend Biotech, listed on the Nasdaq Global Selected Market, has filed its Form 6-K with the SEC, detailing its financial performance and recent business highlights. GenScript advises shareholders and potential investors to exercise caution when dealing with its securities, as the financial results pertain solely to Legend Biotech.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Genscript Biotech Completes Major Share Transfer in Probio Cayman
May 7, 2025

Genscript Biotech Corporation has completed a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman. This transaction, which took place on May 7, 2025, strengthens Genscript’s control over Probio Cayman, increasing its equity interest to approximately 85.09%. This strategic move is likely to enhance Genscript’s market positioning and operational capabilities in the biotech sector.

Genscript Biotech Increases Stake in Probio Cayman with $225 Million Share Purchase
Apr 28, 2025

Genscript Biotech Corporation announced a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman, for approximately US$225.1 million. This transaction will increase Genscript’s equity interest in Probio Cayman from 71.72% to 85.09%, enhancing its control over the subsidiary. The deal, approved by the Board, is considered a connected transaction but is exempt from certain regulatory requirements, reflecting its strategic importance for Genscript’s market positioning and operational control.

Legend Biotech Reports Strong CARVYKTI® Sales for Q1 2025
Apr 15, 2025

Legend Biotech, an associate of Genscript Biotech, announced that CARVYKTI® generated approximately US$369 million in net trade sales for the quarter ended March 31, 2025. This announcement highlights the product’s strong market performance and its potential impact on the company’s financial health and industry standing.

Genscript Biotech Announces 2025 AGM with Key Resolutions
Apr 8, 2025

Genscript Biotech Corporation has announced its 2025 Annual General Meeting, scheduled for May 29, 2025, in Nanjing, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements, re-election of board members, and re-appointment of auditors. Additionally, the company seeks approval to allow its directors to issue new shares, a move that could potentially impact its capital structure and shareholder value.

Genscript Biotech Releases Supplemental Announcement on Legend Biotech’s Financial Results
Mar 14, 2025

Genscript Biotech Corporation announced a supplemental release regarding the financial results of its listed associate, Legend Biotech Corporation, for the fourth quarter and the year ended December 31, 2024. The announcement includes a Chinese translation of Legend Biotech’s press release, originally published in English, detailing financial performance and recent business highlights. Stakeholders are advised to consider investment risks carefully.

Genscript Biotech Reports Significant Profit Boost from Cell Therapy Deconsolidation
Mar 11, 2025

Genscript Biotech reported a significant increase in profit for the year ended December 31, 2024, primarily due to a gain from the deconsolidation of its cell therapy business, amounting to approximately US$3.2 billion. Despite a stable gross profit and a modest revenue growth of 6.1%, the adjusted net profit from continuing operations saw a slight increase of 2.9%, reflecting the company’s strategic adjustments and financial resilience.

Genscript Biotech Announces Legend Biotech’s 2024 Financial Results
Mar 11, 2025

Genscript Biotech Corporation announced the financial results of its associate, Legend Biotech Corporation, for the fourth quarter and year ended December 31, 2024. Legend Biotech, in which Genscript holds a 47.51% stake, filed its financial results with the SEC, highlighting recent business achievements. Shareholders are advised to consider investment risks when dealing with Genscript’s securities.

Genscript Biotech Redesignates Dr. Grossman as Independent Director
Mar 11, 2025

Genscript Biotech Corporation has announced the redesignation of Dr. Ross Allen Grossman from a non-executive Director to an independent non-executive Director, effective March 11, 2025. This change in the board’s composition reflects the company’s strategic focus on strengthening its governance structure, potentially enhancing its industry positioning and stakeholder confidence.

Genscript Biotech Announces Board Composition and Committee Roles
Mar 11, 2025

Genscript Biotech Corporation has announced the composition of its board of directors and the roles they will undertake. The board includes a mix of executive, non-executive, and independent non-executive directors, with various members serving on five established committees. This announcement highlights the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive position in the biotechnology sector.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.